Cinacalcet in the management of primary hyperparathyroidism: Post marketing experience of an Italian multicentre group

Clinical Endocrinology

Volumn 79, Issue 1, 2013, Pages 20-26

  Saponaro, Federica ^a   Faggiano, Antongiulio ^b   Grimaldi, Franco ^c   Borretta, Giorgio ^d   Brandi, Maria Luisa ^e   Minisola, Salvatore ^f   Frasoldati, Andrea ^g   Papini, Enrico ^h   Scillitani, Alfredo ⁱ   Banti, Chiara ^a   Prete, Michela Del ^b   Vescini, Fabio ^c   Gianotti, Laura ^d   Cavalli, Loredana ^e   Romagnoli, Elisabetta ^f   Colao, Annamaria ^b   Cetani, Filomena ^a   Marcocci, Claudio ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^d SC Pediatria   (Italy)

^e UNIVERSITY OF FLORENCE   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g Unità Operativa di Endocrinologia   (Italy)

^h REGINA APOSTOLORUM HOSPITAL   (Italy)

ⁱ CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CINACALCET; PARATHYROID HORMONE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; ASYMPTOMATIC DISEASE; CALCIUM BLOOD LEVEL; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FAMILIAL DISEASE; FEMALE; FOLLOW UP; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; ITALY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; NEPHROLITHIASIS; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; RECURRENT DISEASE; SURGICAL RISK; TREATMENT REFUSAL;

AGED; CALCIUM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; HUMANS; HYPERPARATHYROIDISM, PRIMARY; HYPOCALCEMIA; ITALY; MALE; MIDDLE AGED; NAPHTHALENES; PARATHYROIDECTOMY; PRODUCT SURVEILLANCE, POSTMARKETING; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84875128341     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12108     Document Type: Article

References (24)

1. Marcocci, C., &, Cetani, F., (2012) Clinical practice. Primary hyperparathyroidism. New England Journal of Medicine, 365, 2389-2397.
2. Udelsman, R., Lin, Z., &, Donovan, P., (2011) The superiority of minimally invasive parathyroidectomy based on 1650 consecutive patients with primary hyperparathyroidism. Annals of Surgery, 253, 585-591.
3. Bilezikian, J.P., Khan, A.A., &, Potts, J.T. Jr, (2009) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. Journal of Clinical Endocrinology and Metabolism, 94, 335-339.
4. Nemeth, E.F., Heaton, W.H., Miller, M., et al,. (2004) Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. Journal of Pharmacology and Experimental Therapeutics, 308, 627-635.
5. Cetani, F., &, Marcocci, C., (2012) Cinacalcet in the managment of primary hyperparathyroidism. Expert Review of Endocrinology and Metabolism, 7, 45-53.
6. Peacock, M., Bilezikian, J.P., Klassen, P.S., et al,. (2005) Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 90, 135-141.
7. Peacock, M., Bolognese, M.A., Borofsky, M., et al,. (2009) Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. Journal of Clinical Endocrinology and Metabolism, 94, 4860-4867.
8. Marcocci, C., Chanson, P., Shoback, D., et al,. (2009) Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 94, 2766-2772.
9. Peacock, M., Bilezikian, J.P., Bolognese, M.A., et al,. (2011) Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity. Journal of Clinical Endocrinology and Metabolism, 96, E9-E18.
10. Cetani, F., Saponaro, F., Banti, C., et al,. (2012) Cinacalcet Efficacy in Patients With Moderately Severe Primary Hyperparathyroidism According to the European Medicine Agency Prescription Labeling. Journal of Endocrinological Investigation, 35, 655-660.
11. Falchetti, A., Cilotti, A., Vaggelli, L., et al,. (2008) A patient with MEN1-associated hyperparathyroidism, responsive to cinacalcet. Nature Clinical Practice Endocrinology & Metabolism, 4, 351-357.
12. Moyes, V.J., Monson, J.P., Chew, S.L., et al,. (2010) Clinical Use of Cinacalcet in MEN1 Hyperparathyroidism. International Journal of Endocrinology, 2010, 906163.
13. Filopanti, M., Verga, U., Ermetici, F., et al,. (2012) MEN1-Related Hyperparathyroidism: Response to Cinacalcet and its Relationship With the Calcium-Sensing Receptor Gene Variant Arg990Gly. European Journal of Endocrinology, 167, 157-164.
14. U.F.a.D.A.D.A.P.S.C.H.T., http://www.accessdata.fda.gov/drugsatfda-docs/ label/2008/021688s008lbl.pdf (accessed 6 December 2012).
15. E.M.A.M., http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Assessment-Report-Variation/human/000570/WC500028903.pdf (accessed 6 December 2012).
16. U.F.a.D.A.S.c.t., http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2011/021688s017lbl.pdf (accessed 6 December 2012).
17. Kouvaraki, M.A., Greer, M., Sharma, S., et al,. (2006) Indications for operative intervention in patients with asymptomatic primary hyperparathyroidism: practice patterns of endocrine surgery. Surgery, 139, 527-534.
18. Marcocci, C., &, Cetani, F., (2012) Update on the use of cinacalcet in the management of primary hyperparathyroidism. Journal of Endocrinological Investigation, 35, 90-95.
19. Walker, M.D., &, Silverberg, S.J., (2008) Cardiovascular aspects of primary hyperparathyroidism. Journal of Endocrinological Investigation, 31, 925-931.
20. Yu, N., Donnan, P.T., Flynn, R.W., et al,. (2010) Increased mortality and morbidity in mild primary hyperparathyroid patients. The Parathyroid Epidemiology and Audit Research Study (PEARS). Clinical Endocrinology, 73, 30-34.
21. Leifsson, B.G., &, Ahren, B., (1996) Serum calcium and survival in a large health screening program. Journal of Clinical Endocrinology and Metabolism, 81, 2149-2153.
22. Zanocco, K., Angelos, P., &, Sturgeon, C.,. (2006) Cost-effectiveness analysis of parathyroidectomy for asymptomatic primary hyperparathyroidism. Surgery 140, 874-881; discussion 881-872.
23. Khan, A., Grey, A., &, Shoback, D., (2009) Medical management of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. Journal of Clinical Endocrinology and Metabolism, 94, 373-381.
24. Faggiano, A., Di Somma, C., Ramundo, V., et al,. (2011) Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism. Endocrine, 39, 283-287.